Company Details

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)

ASX Listed
ASX Listed
Biomedical / Biotechnology, Biotech
General Investor Profiling

Company Information

  • Executive Summary

    Executive Summary

    Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is a biotechnology company developing innovative drugs for the treatment of a range of cancers with significant unmet medical need. It is based in Sydney, Australia.

    Its lead program, GDC-0084, is being developed to treat aggressive brain cancer (glioblastoma multiforme [GBM]). There are few treatment options for sufferers of GBM and around 65% of sufferers do not respond to currently available treatments. The condition affects around 133,000 people globally per annum and the potential addressable market is worth more than US$1 billion.

    Kazia licensed GDC-0084 from the world’s most successful cancer drug developer, Genentech, in 2016.  The drug works by effectively “switching off” tumour growth and a Phase 1 trial showed a good safety profile and strong efficacy signals. Of the 47 patients in the trial, 40% achieved a stabilisation in the disease while 21% remained on the study for more than three months. A Phase 2 trial commenced in Q2 2018, with safety and dosing data expected in Q2 2019 and preliminary efficacy results expected in Q4 2019. Kazia is also developing GDC-0084 for other cancers that spread to the brain, such as breast cancer.

    An additional candidate, Cantrixil, is being developed for the treatment of ovarian cancer. A Phase I clinical trial under an IND with the US FDA in patients with ovarian cancer commenced in late 2016. In October 2018, Kazia completed Part A of the Phase 1 study looking at dose escalation and moved to Part B, examining preliminary efficacy. Results are expected in Q3 2019.

    Request Information 

    • Lead program, GDC-0084, sourced from the world’s most successful cancer drug developer, Genentech
    • Experienced team with extensive backgrounds in big pharma and biotech
    • Around 65% of GBM sufferers do not respond to current treatments
    • Multiple shots on goal with collaborations progressing in other cancers; largely funded by participating hospitals

    16 employees

    Partnership with big pharma or M&A.

  • Company Highlights

    Company Highlights

    • Lead program, GDC-0084, sourced from the world’s most successful cancer drug developer, Genentech
    • Phase 1 data showed favourable safety profile and evidence of efficacy
    • High unmet need: one existing drug effective in just 35% of patients and no front-runner in development
    • Collaborations progressing in other cancers; largely funded by participating hospitals
    • Second program, Cantrixil, in an ongoing Phase I study with preliminary evidence of activity
    • Four data read-outs from clinical trials in CY2019, with significant potential to drive value and potential partnering
    • Company is well-funded to complete ongoing studies after institutional placement
  • Board & Management

    Board & Management

    Dr James Garner

    Dr James Garner

    Chief Executive Officer & Executive Director
    Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global...

    Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.

    Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.  Dr Garner is a member of the Australian Institute of Company Directors.

    Bryce Carmine

    Bryce Carmine

    Non-Executive Director
    Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales...

    Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company’s executive committee.

    Mr Carmine previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly.

    During his career with Lilly Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea.

    Mr Carmine was appointed as a director of the Company in June 2015 and is considered to be an independent director.

    Steven Coffey

    Steven Coffey

    Non-Executive Director
    Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since...

    Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.

    Mr Coffey is a registered company auditor and audits a number of large private companies as well as a number of not-for-profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of two private ancillary funds (PAFs).

    Mr Coffey was appointed as a director to the Company in November 2012 and is considered to be an independent director.

    Iain Ross

    Iain Ross

    Chairman & Non-Executive Director
    Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and is currently Chairman of e-Therapeutics plc (LSE:ETX), Redx Pharma plc (LON:REDX) and Biomer Technology Limited. During his career, Mr Ross has held senior...

    Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and is currently Chairman of e-Therapeutics plc (LSE:ETX), Redx Pharma plc (LON:REDX) and Biomer Technology Limited.

    During his career, Mr Ross has held senior positions at multinational companies, Sandoz AG, Hoffman La Roche, and Celltech Group PLC and been a Chairman, CEO and Director of several biotech companies. He is a qualified Chartered Director and former Vice Chairman of the Council of Royal Holloway, London University.

    Mr Ross was appointed as a director of the Company in July 2015 and is considered to be an independent director.

    Kate Hill

    Kate Hill

    Company Secretary
    Kate has over 20 years’ experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings,...

    Kate has over 20 years’ experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment.

    In addition to her role at Kazia, Kate is a Non-Executive Director of two ASX listed companies, CountPlus Limited (CUP) and Elmo Software Limited (ELO), and Chairs their Audit and Risk Committees in both cases.

    Kate is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.

  • Company News
  • Contact Details

    Contact Details